Surgiderm® - Dermal Fillers

The product is manufactured by Corneal Group which is currently part of Allergan. They have based the manufacturing on their patented cross-linking process: the “3D Hyaluronic Acid Matrix Technology”, one claimed to allow uniform and greater numbers of cross-link structures thus enabling maximum protection against degradation. This increases the chances of lasting longer than other hyaluronic based fillers. Launch in the UK took place in 2006, meaning only a few practitioners could be using it by now. Generically it is a Non-animal stabilized hyaluronic acid made by bacterial fermentation of streptococci bacteria and does not require skin tests before treatment. The hyaluronic acid gets totally broken down over months, exhausting the filler. It is licensed as a medical device which should be used by qualified medical members only.

Product range formulations include Surgiderm 18 which is suitable for fine lines like laughter lines, smoker lines and peri-oral lines.Surgiderm 24 XP is best for deep lines and wrinkles, and also enhancing the vermillion border-border on the lips. Surgiderm 30 can treat deep lines, wrinkles and deep depressions in the skin.Surgiderm 30 XP is designed for treatment of medium-deep skin depressions, volume enhancements for example cheek atrophy and sunken areas plus enhancement of the vermillion border. Surgilips is mainly injected into lips and peri-oral and can equally fill smoker’s lines, redefining vermillion border and lip volume increase.Finally,Surgilift® Plus is best for replenishment of the hyaluronic acid lost through ageing, thus improving its elasticity and tone in areas like face, neck, décolletage and hands. It cannot be used on people with known hypersensitivity to hyaluronic acid, pregnant and breast feeding women. It can last for 9 - 12 months. Effects can be transient eryrthema (redness), swelling, discomfort at the implant area, usually recovering instantaneously in 1-2 days after treatment. Hypersensitivity-related effects have been reported in 1 out of every 2000 patients. Rare cases of granuloma, urticaria and superficial necrosis are reported in 1 out of 15,000 treated cases. Ranging around £250 to £400, costs depend on area, amount, practitioner and type.